Triple fixed-dose combination therapy: Back to the past

Hypertension

Volumn 54, Issue 1, 2009, Pages 19-22

  Black, Henry R ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Skirball 9U ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS HYDROCHLORTHIAZIDE; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; ATENOLOL PLUS CHLORTALIDONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; BUTALBITAL PLUS RESERPINE; CALCIUM ANTAGONIST; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CHLORTALIDONE; CHLORTHALIDONE PLUS CLONIDINE; CLONIDINE; CLORPRES; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; GANGLION BLOCKING AGENT; HEXAMETHONIUM PLUS HYDRALAZINE; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; VASOPEPTIDASE INHIBITOR; VERATRUM ALKALOID;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HEADACHE; HUMAN; HYPERTENSION; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VERATRUM;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 67649855145     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.132688     Document Type: Note

References (9)

1. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32-39.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. ypertension. 2003;42:1206-1252.
3. Cushman WC, Ford CE, Cutler CE, Margolis K, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwanchuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Betterncourt J, Walsh S, for the ALLHAT Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hyperten. 2002;4:393-405.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
5. Rosendorff C, Black HR, Cannon CP, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. The treatment of hypertension in the prevention and management of ischemic heart disease: a statement from the American Heart Association Councils for High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
7. Black HR. The paradigm has shifted to systolic blood pressure. J Hum Hypertens. 2004;18:S3-S7.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk randomized angiotensin-converting- enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.